Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS: −624.8%
Free cash flow: −108.8%

Quarter to September 2026, against a year earlier

103.89 7.30 +7.56%

Follow SYRE

Alert me

Market cap: $9.2B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −3.82
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Spyre Therapeutics, Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 3, 2026 · accepted 4:01 PM ET · Document on sec.gov · Filing index

Red flags

Short cash runway Nov 3, 2026
Spyre Therapeutics, Inc.’s cash and short-term investments cover about 1.2 quarters of its operating cash burn

10-Q filed Nov 3, 2026 · The filing · sec.gov
Share dilution Nov 3, 2026
Shares outstanding rose 22.4% in a year, to 95.0 million

10-Q filed Nov 3, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 31 added · 25 removed · 37 modified; 4 with only figures updated

Spyre Therapeutics, Inc. 10-Q filed Nov 3, 2026

Red flags

What changed

Stockrow Weekly